Notice of Final Results

RNS Number : 0992X

AdvancedAdvT Limited

19 July 2024

AdvancedAdvT Limited

Notice of final results - 22 July 2024

AdvancedAdvT Limited (AIM: ADVT, "AdvT"), the international software solutions provider for the business solutions, healthcare compliance, and human capital management sectors, will publish its results for the eight months to 29 February 2024 (being AdvT's financial year end) on Monday 22 July 2024.

Enquiries:

AdvancedAdvT Limited
Vin Murria, Chairperson Gavin Hugill, Chief Financial Officer	c/o Meare Consulting

Singer Capital Markets (Nominated Adviser and Broker)	Tel: 020 7496 3000
Philip Davies / Asha Chotai / Sam Butcher

KK Advisory (Investor Relations)	Tel: 020 7039 1901
Kam Bansil

Meare Consulting
Adrian Duffield	Tel: 07990 858548

Note to Editors

AdvancedAdvT Limited (AdvT) provides software solutions and platforms across two business transformational areas: business solutions & healthcare compliance, and human capital management.

The Group's operations are IBSS (financial management software), CHKS (AI based healthcare intelligence compliance and accreditation software), Retain (global resource planning and talent management software) and WFM (workforce management software provider).

AdvT is an agent for change. The Group enables the delivery of Artificial Intelligence ("AI"), data analytics and business intelligence, all of which are key future drivers for growth in these sectors where long term digitisation trends are set to transform the workplace for professionals.

AdvT is developing both organically and through acquisitions, by expanding its presence across adjacent markets, geographical boundaries and digital sectors.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NORSFFFEUELSESW